12.05.2015 • News

Brenntag and Hexion Expand Distribution Agreement for Epoxy Resins to Austria

Brenntag and Hexion announced an expanded cooperation on Epoxy Resins in Austria, effective June 1, 2015.

The expanded agreement is said to strengthens the channel partner relationship the two companies have in Europe. Brenntag already represents Hexion in the following countries: Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland, the United Kingdom, Croatia, Czech Republic, Poland, Romania, Serbia, Slovakia and Slovenia.

"With this step to Austria, we expand our excellent business relationship with Hexion yet again, providing innovative new epoxy products, including water-based technologies designed to serve construction end-markets in a variety of coatings applications," said Martin Rimmer, European Marketing Manager, Coatings & Construction for Brenntag Europe, Middle East and Africa.

"We are pleased to further expand our relationship with Brenntag, which has an excellent track record representing our epoxy products and a strong sales force with the necessary technical knowledge and commitment to grow our joint business," said Wouter Jongepier, Business Director, Epoxy Specialties EMEA, Hexion. "Our two companies will provide improved service levels, stronger product stocking, and timely technical support to critical industries operating in Austria."

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read